These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31187454)

  • 21. Microglia activation in Niemann-Pick disease, type C1 is amendable to therapeutic intervention.
    Cougnoux A; Drummond RA; Collar AL; Iben JR; Salman A; Westgarth H; Wassif CA; Cawley NX; Farhat NY; Ozato K; Lionakis MS; Porter FD
    Hum Mol Genet; 2018 Jun; 27(12):2076-2089. PubMed ID: 29617956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1.
    Holzmann C; Witt M; Rolfs A; Antipova V; Wree A
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1).
    Tortelli B; Fujiwara H; Bagel JH; Zhang J; Sidhu R; Jiang X; Yanjanin NM; Shankar RK; Carillo-Carasco N; Heiss J; Ottinger E; Porter FD; Schaffer JE; Vite CH; Ory DS
    Hum Mol Genet; 2014 Nov; 23(22):6022-33. PubMed ID: 24964810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Niemann-Pick C1 mouse models, glial-only expression of the normal gene extends survival much further than do changes in genetic background or treatment with hydroxypropyl-beta-cyclodextrin.
    Marshall CA; Watkins-Chow DE; Palladino G; Deutsch G; Chandran K; Pavan WJ; Erickson RP
    Gene; 2018 Feb; 643():117-123. PubMed ID: 29223359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A therapy with miglustat, 2-hydroxypropyl-ß-cyclodextrin and allopregnanolone restores splenic cholesterol homeostasis in Niemann-pick disease type C1.
    Neßlauer AM; Gläser A; Gräler M; Engelmann R; Müller-Hilke B; Frank M; Burstein C; Rolfs A; Neidhardt J; Wree A; Witt M; Bräuer AU
    Lipids Health Dis; 2019 Jun; 18(1):146. PubMed ID: 31248418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases.
    Megías-Vericat JE; García-Robles A; Company-Albir MJ; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Casanova B; Poveda JL
    Neurol Sci; 2017 May; 38(5):727-743. PubMed ID: 28155026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.
    Ottinger EA; Kao ML; Carrillo-Carrasco N; Yanjanin N; Shankar RK; Janssen M; Brewster M; Scott I; Xu X; Cradock J; Terse P; Dehdashti SJ; Marugan J; Zheng W; Portilla L; Hubbs A; Pavan WJ; Heiss J; Vite CH; Walkley SU; Ory DS; Silber SA; Porter FD; Austin CP; McKew JC
    Curr Top Med Chem; 2014; 14(3):330-9. PubMed ID: 24283970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of the Anionic Hydroxypropyl-β-cyclodextrin:Poly(decamethylenephosphate) Polyrotaxane and Evaluation of its Cholesterol Efflux Potential in Niemann-Pick C1 Cells.
    Egele K; Samaddar S; Schneider N; Thompson D; Wenz G
    J Mater Chem B; 2019 Jan; 7(4):528-537. PubMed ID: 31372225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.
    Cougnoux A; Clifford S; Salman A; Ng SL; Bertin J; Porter FD
    Mol Genet Metab; 2018 Dec; 125(4):345-350. PubMed ID: 30392741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Niemann-Pick disease type C presenting as very early onset inflammatory bowel disease.
    Dike CR; Bernat J; Bishop W; DeGeeter C
    BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31352388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
    Singhal A; Szente L; Hildreth JEK; Song B
    Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of age of onset and clinical severity in Niemann-Pick disease type C1 with lysosomal abnormalities and gene expression.
    Baxter LL; Watkins-Chow DE; Johnson NL; Farhat NY; Platt FM; Dale RK; Porter FD; Pavan WJ; Rodriguez-Gil JL
    Sci Rep; 2022 Feb; 12(1):2162. PubMed ID: 35140266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Two Liver Treatment Strategies in a Mouse Model of Niemann-Pick-Disease Type C1.
    Ebner L; Gläser A; Bräuer A; Witt M; Wree A; Rolfs A; Frank M; Vollmar B; Kuhla A
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.
    Yasmin N; Ishitsuka Y; Fukaura M; Yamada Y; Nakahara S; Ishii A; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Okada Y; Nishikawa J; Ichikawa A; Iohara D; Hirayama F; Higaki K; Ohno K; Matsuo M; Irie T
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial of
    Bremova-Ertl T; Ramaswami U; Brands M; Foltan T; Gautschi M; Gissen P; Gowing F; Hahn A; Jones S; Kay R; Kolnikova M; Arash-Kaps L; Marquardt T; Mengel E; Park JH; Reichmannová S; Schneider SA; Sivananthan S; Walterfang M; Wibawa P; Strupp M; Martakis K
    N Engl J Med; 2024 Feb; 390(5):421-431. PubMed ID: 38294974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin.
    Carradori D; Chen H; Werner B; Shah AS; Leonardi C; Usuelli M; Mezzenga R; Platt F; Leroux JC
    Small; 2020 Nov; 16(46):e2004735. PubMed ID: 33079457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and distribution of 2-hydroxypropyl-β-cyclodextrin following a single intrathecal dose to cats.
    Kao ML; Stellar S; Solon E; Lordi A; Kasica N; Swain G; Bagel JH; Gurda BL; Vite CH
    J Inherit Metab Dis; 2020 May; 43(3):618-634. PubMed ID: 31707730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-hydroxypropyl-beta-cyclodextrin raises hearing threshold in normal cats and in cats with Niemann-Pick type C disease.
    Ward S; O'Donnell P; Fernandez S; Vite CH
    Pediatr Res; 2010 Jul; 68(1):52-6. PubMed ID: 20357695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-treatment with probucol does not improve lung pathology in hydroxypropyl-β-cyclodextrin-treated Npc1
    Erickson RP; Borbon IA
    J Appl Genet; 2019 May; 60(2):175-178. PubMed ID: 30815842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients.
    García-Robles AA; Company-Albir MJ; Megías-Vericat JE; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Alcalá-Vicente C; Galeano I; Casanova B; Poveda JL
    J Neurol Sci; 2016 Jul; 366():65-67. PubMed ID: 27288778
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.